The difference between stopping the drug and leaving the study, and what happens to data already collected. Written for trial participants and the people advising them.

In this file:

·        The 3 decisions people call "quitting," and why they are not the same

·        What the regulation actually guarantees you

·        What happens to data already collected, and what stops

·        Why the site still asks for one more visit

"I think I'm done," Walter says.

Nani doesn’t ask why. Her first question is the one almost nobody expects.

"Done with which part?"

That sounds like a stall but it’s not. There are 3 different decisions hiding inside the sentence "I want out," they have 3 different consequences, and most people who say it are only trying to make one of them.

1. Stop the study drug. You stop taking it. You keep coming to visits, you keep being assessed, and you stay in the study. This is common, it’s completely allowed, and for a lot of people it’s the decision they actually wanted.

2. Stop the visits. You stop coming in, but you have not withdrawn your consent. Sites will usually offer something smaller: a phone call instead of a visit, a shorter version of the assessment, or permission to check your medical records for the outcome that matters. Saying yes to the smallest of those is worth far more than most people realise, and it costs you almost nothing.

3. Withdraw consent. You end your participation entirely. Nothing further is collected about you.

Walter, it turns out, wanted number 1. The drug was making him feel wrong in the afternoons and he had decided he was finished with it, and he assumed that meant he was finished with everything. He wasn’t, and nobody had ever explained that those could come apart.

The right to stop isn’t a courtesy the site extends. It’s a required element of the consent form, and the regulation spells out the words.

Under 21 CFR 50.25(a)(8), the consent must include "a statement that participation is voluntary, that refusal to participate will involve no penalty or loss of benefits to which the subject is otherwise entitled, and that the subject may discontinue participation at any time without penalty or loss of benefits to which the subject is otherwise entitled."

Read the second half twice. No penalty and no loss of benefits you are otherwise entitled to. Your regular care is not a benefit the study gets to withdraw. Nobody is allowed to make your ordinary treatment contingent on staying in a trial.

You also don’t have to give a reason. ICH GCP is explicit that a participant is not obliged to give reasons for withdrawing early, and asks the investigator to "make a reasonable effort to ascertain the reason(s), while fully respecting the subject's rights."

So when the coordinator asks why, they’re following a guideline, not pushing back. And you’re allowed to say you would rather not discuss it. Both of those things are true at once, and knowing that makes the conversation easier on both sides of the desk.

This is the part people are least often told and most often surprised by.

Data collected about you up to the moment you withdraw stays in the study. FDA's guidance on this, issued in October 2008, is not ambiguous: "the data collected on the subject to the point of withdrawal remains part of the study database and may not be removed."

The reason is not administrative convenience. It’s arithmetic. If everyone who felt worse could be erased from a trial, every drug would look better than it is, and the trial would be measuring who stayed rather than what the drug did. Removing your data does not protect you, it distorts the answer for everyone who comes after you.

ICH E6(R3), the current version of Good Clinical Practice, now says this directly in its section on participants who do not reach the end of the trial, noting that loss of already collected data "may bias results and may lead to, for example, inaccurate conclusions regarding the safety profile of the investigational product." The obligation to keep accurate case histories on everyone who received the drug or served as a control sits in regulation too, at 21 CFR 312.62(b).

Now what stops, which is the half that matters if privacy is your concern.

No new data. An investigator may ask whether you are willing to allow continued follow up after you withdraw, but they must obtain your informed consent for that limited participation. Withdrawal without that agreement means collection ends.

No going into your records. If you decline continued follow up, the investigator may not access your medical record or other confidential records for study purposes.

One carve out. Public records may still be consulted, including those establishing survival status. That is worth knowing rather than discovering later, and it is a fair thing to ask about at the time.

If you gave blood or tissue, the obvious next question is what happens to it.

The honest answer is that FDA's guidance on withdrawal addresses data and does not address already collected biological samples at all. There is no sentence in it to quote you either way.

Which means the answer for your study is in your consent form, not in a federal rule. Consent forms usually say what happens to samples, whether they are destroyed on request, whether they are kept for future research, and whether they have been stripped of identifiers, in which case pulling yours back out may not be technically possible.

Ask before you sign. Ask again before you withdraw. And treat anybody who tells you confidently what the law requires for samples as somebody who has not read the guidance, because it does not say.

You have decided to stop, and the coordinator asks you to come in one more time. It sounds like negotiation. It usually is not.

An early termination visit exists mostly for your benefit. It’s where the last safety labs get drawn, where an unresolved side effect gets checked rather than left, where any remaining study drug gets returned and counted, and where you get told what happens next, including whether you will hear the study's results.

There is a common misunderstanding worth clearing up here. No FDA regulation sets a safety follow up period. There is no federal 30 day rule. The regulation, at 21 CFR 312.64(b), requires the investigator to report serious adverse events to the sponsor immediately and to record other adverse events and report them on the timetable specified in the protocol. So a 30 day follow up window, where one exists, is written into your protocol by the people who designed the study, which means it can be discussed like anything else in a protocol.

You can decline the visit. You are allowed to. Just decline it knowing what it was for.

Note to File. For coordinators. "Done with which part" is the highest yield question in this entire job, and it belongs in the conversation before anyone reaches for a withdrawal form. A large share of what gets logged as withdrawal of consent is really discontinuation of study drug by someone who was never told those were separable. Write down what you offered, in the participant's own words where you can: phone follow up, records only, vital status. An offer that was declined is documentation. An offer that was never made is a gap, and it’s a gap that shows up in the study report as missing data with no explanation attached.

Leaving a trial is 3 different decisions, not one. You can stop the study drug and stay in the study, you can stop coming to visits without withdrawing your consent, or you can withdraw entirely. 21 CFR 50.25(a)(8) requires your consent form to tell you that participation is voluntary and that you may stop at any time without penalty or loss of benefits you are otherwise entitled to, and you never owe anyone a reason. Data already collected stays in the database, because removing it would bias the answer for everyone else, and FDA's October 2008 guidance says so explicitly. What stops is future collection: no new data and no access to your medical records without your fresh agreement, with public records such as survival status as the one stated exception. On biological samples, FDA's guidance is silent, so the answer for your study is in your consent form. And the last visit the site asks for is mostly for you. Walter stopped the drug, kept the visits, and finished the study.

Reply to this email or leave a comment on the newsletter: have you seen someone stop the study drug but stay in the study? Did anyone explain the difference to them? Every query gets read, and the best ones get answered in a future issue.

Know someone training for their first coordinator job, or thinking about one? Send them this issue with your own referral link below, so the share counts. The Open Site File is written for exactly that person.

The Open Site File is one part of Root to Rx, and we all work toward the same thing: making clinical research easier to understand and harder to misrepresent. Wednesday, Plain Talk opens in The Root Room, where a real health claim tries to work on someone, then takes it apart in plain language, with the receipts. Sunday, The Roots, on LinkedIn, is a letter for the people whose family treats them as the medical desk. And every Tuesday, The Open Site File shows you the inside of the site, where the people who make trials run actually work. Different doors, one mission: more people who understand how medicine gets made, and fewer people misled about it.

·        Previous issue: Issue 17, Version History, why consent is a document

·        Next issue: Issue 19, what a clinical research assistant does

·        Related: Issue 16, what happens when a patient misses a study visit

·        For the people whose family treats them as the medical desk: The Roots, our weekly letter.

·        Why the rules read the way they do, and the history behind them: Version History.

·        Helping a patient or family member look for a study? A walkthrough of the public trial registries.

·        Patient materials, including a medication and supplement log modeled on the conmed logs used in trials: shop.roottorx.com.

·        21 CFR 50.25, Elements of informed consent (eCFR)

·        21 CFR 312.62, Investigator recordkeeping and record retention (eCFR)

·        21 CFR 312.64, Investigator reports (eCFR)

·        FDA, Data Retention When Subjects Withdraw from FDA-Regulated Clinical Trials. Guidance, October 2008

·        ICH E6(R3) Good Clinical Practice, section 2.9 on participants who discontinue or withdraw

·        ICH E9, Statistical Principles for Clinical Trials, section 5.2.1 on intention to treat

•  •  •

The Open Site File is general education about how clinical research sites work. It is not regulatory, legal, or medical advice, and it is not tied to any specific study, sponsor, or employer. If you are in a trial, your study team and your own doctor are the right people to ask about your situation. Always follow your own site’s SOPs, your protocol, and your PI and QA team. Names and characters are invented composites.

Disclosure: The Open Site File is part of Root to Rx, published independently by Open Label Media LLC. Views expressed are personal views of Justin Yamashita and do not represent his employer or any affiliated organization. No employer resources or proprietary information are used. Every claim is sourced from publicly available materials.

Filed by Justin Yamashita, MSc., Open Label Media

Next in the file: Issue 19, the real line between a research assistant and a coordinator.